$50.310
-1.001 (-1.99%)At close
ETON News
ETON Events
Eton and Aquestive Sign Exclusive License Agreement for LIBERVANT
Eton Pharmaceuticals (ETON) and Aquestive Therapeutics (AQST) announced that they have entered into an exclusive license agreement and a supply agreement covering the U.S. and its territories for LIBERVANT, or diazepam, buccal film, an Orphan Drug-designated, differentiated treatment for seizure clusters in patients with epilepsy. Eton anticipates commercial availability of LIBERVANT in April 2027, subject to final FDA approval. The agreement grants Eton exclusive U.S. commercialization rights to LIBERVANT and adds a new growth driver to Eton's expanding rare disease portfolio. The product builds on Eton's experience commercializing differentiated dosage forms, engaging specialist physicians, and supporting patients and caregivers through treatment education, advocacy, and programs designed to maximize therapy access and minimize affordability barriers. LIBERVANT's Orphan Drug Designation and specialist treatment setting complement Eton's focus on medicines requiring targeted education, patient support, and close engagement with healthcare professionals and patient advocacy groups. The agreement also builds on Eton's experience supporting pediatric patients and families, where treatment decisions often involve caregivers and confidence in administration is important. Eton plans to establish a dedicated neurology team supported by its existing commercial infrastructure. Its commercialization approach will draw on experience acquiring and relaunching specialty medicines, including INCRELEX, GALZIN, and HEMANGEOL, as well as established capabilities in advocacy partnerships, community engagement, and treatment education.
Eton Pharmaceuticals Launches Impavido Capsules
Eton Pharmaceuticals announced that the company has launched Impavido capsules. Eton Pharmaceuticals now holds exclusive commercialization rights for Impavido in the United States.
Stock Futures Steady as S&P 500 Hits Record High
Stock futures are mostly flat after the S&P 500 closed at a record high Thursday, as investors balance easing inflation pressures and strong corporate earnings against renewed geopolitical risks.The inflation backdrop remains supportive for equities. July CPI and PPI both came in softer than expected, reducing concerns that the Federal Reserve will need to raise interest rates at its September meeting. PPI was unchanged in July after declining 0.1% in June, while the latest CPI data showed inflation continuing to moderate. The market is increasingly focused on whether the combination of cooling inflation and a weakening labor market will give the Fed room to ease policy later this year.AI and semiconductor stocks remain a major source of strength. Applied Materials is falling in premarket trading despite reporting strong results and raising its outlook. Meanwhile, memory and storage stocks including SanDisk, Seagate Technology and Micron have been strong following upbeat industry forecasts.Brent crude is approaching $90 a barrel after the U.S. threatened an indefinite naval blockade of Iran as efforts to reach a ceasefire remain stalled. Higher oil prices could complicate the Fed's inflation outlook if they persist, particularly with gasoline prices already above $4 a gallon.In pre-market trading, S&P 500 futures rose 0.08%, Nasdaq futures rose 0.26% and Dow futures fell 0.16%.Check out this morning's top movers from around Wall Street, compiled by The Fly.HIGHER -Redditup 11% after being chosen for admission into the S&P 500 indexSanDiskup 6% after JPMorgan initiated coverage of the stock with an Overweight rating and $2,250 price target following the company's investor day meetingWayfairup 5% after Bernstein upgraded shares to Outperform with a price target of $125, up from $100Fox Corp.up 3% after Wells Fargo upgraded the stock to Overweight with a price target of $80, up from $65UP AFTER EARNINGS -Eton Pharmaceuticalsup 27%DOWN AFTER EARNINGS -ARS Pharmaceuticalsdown 15%Quince Therapeuticsdown 9%Applied Materialsdown 6%Outlook Therapeuticsdown 4%Sigma Lithiumdown 2%
S&P 500 Rises as Oil Prices Fall
The major averages closed broadly higher as oil prices fell and investors digested softer-than-feared inflation data and another slate of corporate earnings reports. Communication services was the best-performing sector in the benchmark index, bolstered by 5% gains out of Netflixas well as strong performance by Telecom Services names. Basic Materials names underperformed however as metals prices continued their range-bound trading in spite of benign inflation data this week.The Fed outlook has become somewhat more favorable for equities following the inflation data and the weak July employment report. Meanwhile, oil prices were down as concerns over global demand and rising U.S. crude inventories offset continued geopolitical risks surrounding Iran and the Strait of Hormuz.In the opening hour of the evening session, S&P 500 e-Minis, Dow Industrials, and Nasdaq 100 futures are trading flat. In commodities, WTI crude oil is just above $81 a barrel.Check out this evening's top movers from around Wall Street, compiled by The Fly.HIGHER AFTER EARNINGS -Eton Pharmaceuticalsup 20.4%Heartflow.up 17.7%Nu Holdingsup 7.5%AudioEye, Inc.up 2.6%ALSO HIGHER -Redditup 11.1% on S&P 500 inclusionDOWN AFTER EARNINGS -Intellicheck, Inc.down 17.9%ARS Pharmaceuticalsdown 13.4%Globant S.A.down 12.7%Applied Materialsdown 4.9%HawkEye 360down 2.8%ALSO LOWER -Birkenstock Holding plcdown 4.4% after equity offering
Company Adjusts FY26 EBITDA Margin to 35%
Sees at least a 35% adjusted EBITDA margin for FY26, an increase from prior guidance of at least 30%. The revised adjusted EBITDA guidance is inclusive of a $3M licensing payment for ASN-001 which will be expensed in Q3, incremental second half R&D expenses related to ASN-001's bioavailability study, and a potential, one-time $4M commercial milestone payment related to Alkindi Sprinkle sales performance, which may be triggered in Q4 of 2026.
This page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.